Global Diabetic Nephropathy Market Report, published by Variant Market Research, forecast that the global market is expected to reach $3,826 million by 2024 from $2,410 million in 2016, growing at a CAGR of 5.9% from 2016 to 2024. By geography, Asia-Pacific and Europe are expected to grow at a CAGR of 7.1% and 6.1%, respectively, during the forecast period.
Some of the drivers of global diabetic nephropathy market are increasing obesity and diabetes among population, rising investments by major companies for drug discovery & development, growing number of patients suffering from various kidney diseases and rising awareness. Moreover, several initiatives by government and NGOs for increasing awareness and rising scope of combination therapies would provide several growth opportunities.
Mode of treatment and geography are the major segments considered in the global diabetic nephropathy market. Mode of treatment is bifurcated into drug modifying therapies (angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers (ARBs), diuretics, calcium channel blockers (CCBs), renin inhibitors, connective tissue growth factor inhibitor (CTGF), antioxidant inflammation modulator (AIM), monocyte chemoattractant proteins (MCP) inhibitors, endothelin-A receptors antagonist (ETAR), G protein-coupled receptors (GPCRs) and others) and others. Drug modifying therapies is anticipated to dominate the mode of treatment segment with largest market share and fastest CAGR during the forecast period.
Geographically, the global diabetic nephropathy market is categorized into North America, Europe, Asia-Pacific, and Rest of the world (RoW). North America and Europe dominated the market with largest share of 41.1% and 26.8%, respectively, in 2016. In terms of growth, Asia-Pacific is likely to grow with fastest CAGR, driven by, presence of high number of diabetic population, increasing awareness and improving healthcare infrastructure.
The major players operating in the market include Bayer AG, Novartis AG, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Mesoblast Ltd., Ampio Pharmaceuticals Inc., Reata Pharmaceuticals, GenKyoTex S.A., and ChemoCentryx Inc., among others.